You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

237 Results
Guidelines and Advice
Status: Current
Sep 2019
Guidelines and Advice
Status: Current
ID: N/A
Version: N/A
Oct 2019
Guidelines and Advice
Status: Current
ID: GL 17-12
Version: N/A
Sep 2019
Guidelines and Advice
Status: Current
ID: pet 2019-1
Version: N/A
Nov 2019
Guidelines and Advice
Status: Current
Oct 2019
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
ODB - General Benefit
    capecitabine
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
capecitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Nivolumab - Neoadjuvant Treatment for Non-Small Cell Lung Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
nivolumab,
gemcitabine,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2024
Guidelines and Advice
Status: Current
ID: GL 1-14
Version: 3
Oct 2019
Guidelines and Advice
Status: In-Review
ID: GL 5-3ORG
Version: 2
Apr 2019

Pages